Tonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million

• Tonix posted Q2 2026 net sales of $13.54 million, rising from $2 million a year earlier; TONMYA contributed about $11 million.
• Net loss available to common stockholders narrowed to $40.55 million, or $2.44 per share, from $28.27 million, or $3.86 per share.
• R&D expenses climbed to $19.42 million from $10.82 million; SG&A rose to $35.96 million from $16.2 million on launch-related investment.
• Cash and cash equivalents totaled $176.23 million at June 30, 2026; cash runway expected into early Q2 2027.
• TONMYA prescriptions more than doubled quarter-over-quarter to 12,592; payer coverage expanded to about 136 million covered lives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.